Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

New drug for rheumatoid arthritis to be launched

Certolizumab pegol (Cimzia), a pegylated antitumour necrosis factordrug for the treatment of moderate to severe active rheumatoidarthritis, will be available in the UK from 23 October 2009

Certolizumab pegol (Cimzia), a pegylated antitumour necrosis factor drug for the treatment of moderate to severe active rheumatoid arthritis, will be available in the UK from 23 October 2009.

Certolizumab pegol, given as a subcutaneous injection in combination with methotrexate, is indicated for adult patients inadequately responsive to disease-modifying antirheumatic drugs. It can also be given as monotherapy in patients unsuitable for methotrexate therapy.

According to UCB Pharma, the manufacturer of the drug, certolizumab pegol has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.

Certolizumab pegol is a tumour necrosis factor alpha (TNFa) inhibitor. TNFa is a pro-inflammatory cytokine with a central role in inflammatory processes.

Citation: The Pharmaceutical Journal URI: 10982005

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.